JH
Jim Harding Portfolio
Invests via Propel Bio Management LLC | Managed by Leen Kawas, Xue Hua
Invests via Propel Bio Management LLC
Managed by Leen Kawas, Xue Hua
Automatically Tracked
Jim Harding Profile
With a strong foundation in finance and entrepreneurship, Jim Harding has established himself as an influential player in the business community. Known for his strategic foresight, he has successfully led various ventures that bridge traditional industries with innovative practices. His expertise spans across operational leadership and growth initiatives, positioning him to impact not just company trajectories but also sector dynamics. As a frequent collaborator on high-stakes projects, Harding cultivates partnerships that enhance market opportunities while driving competitive advantage.
With a strong foundation in finance and entrepreneurship, Jim Harding has established himself as an influential player in the business community. Known for his strategic foresight, he has successfully led various ventures that bridge traditional industries with innovative practices. His expertise spans across operational leadership and growth initiatives, positioning him to impact not just company trajectories but also sector dynamics. As a frequent collaborator on high-stakes projects, Harding cultivates partnerships that enhance market opportunities while driving competitive advantage.
Investment Philosophy & Strategy
Jim Harding leverages his extensive entrepreneurial experience to identify transformative investment opportunities within traditional industries. His focus lies in harnessing innovative practices that enhance operational efficiencies and foster sustainable growth. By capitalizing on emerging trends, he strategically aligns resources to maximize value creation while mitigating competitive risks. His collaborative approach enables the cultivation of strategic partnerships that drive impactful results across sectors. With a keen eye for business model evolution, he consistently seeks ventures poised for significant market disruption.
Jim Harding leverages his extensive entrepreneurial experience to identify transformative investment opportunities within traditional industries. His focus lies in harnessing innovative practices that enhance operational efficiencies and foster sustainable growth. By capitalizing on emerging trends, he strategically aligns resources to maximize value creation while mitigating competitive risks. His collaborative approach enables the cultivation of strategic partnerships that drive impactful results across sectors. With a keen eye for business model evolution, he consistently seeks ventures poised for significant market disruption.
Disclaimer: This Portfolio is derived from and computed based on publicly available data from SEC filings.
Gain and growth charts are calculated per selected timeframe:
-12.36%
Gain +0.01%
Monthly
-0.45%
Yearly
-5.24%
Drawdown
60.42%
$177.13M
Equity
Holdings
$177.13M
Investment
$153.81M
$1.18M
Profit +$11,515.44
Realized
-$22.14M
Unrealized
$23.32M
Dividends
$5.14M
Goals
Avg. 26.5% completed goals
Yearly
Gain > 5% 2026
Yearly
Gain < 20% 2026
Today
Compared To Yesterday
Gain
0.01%
Profit
$11,515.44
Win %
49%
This Week
Compared To Last Week
Gain
0.01%
Profit
$11,515.44
Win %
49%
This Month
Compared to last month
Gain
-0.67%
Profit
-$1.2M
Win %
49%
This Year
Compared to last year
Gain
-9.31%
Profit
-$2.7M
Win %
51%
ARTV Artiva Biotherapeutics Inc.
+6.75%
+$79,039.26 
IMUX Immunic, Inc.
+6.04%
+$185,237.54 
CMPS Compass Pathways plc Depositary Receipt
+5.87%
+$497,172.83 
TRVI Trevi Therapeutics Inc.
+5.57%
+$167,851.5 
CLDX Celldex Therapeutics Inc.
+4.37%
+$172,086.84 
EYPT EyePoint Pharmaceuticals Inc.
+4.24%
+$114,387.25 
OVID Ovid Therapeutics Inc.
+4.07%
+$82,931.13 
NUVB Nuvation Bio Inc.
+3.36%
+$52,687.36 
ALDX Aldeyra Therapeutics Inc.
+2.92%
+$36,530.3 
CRVS Corvus Pharmaceuticals Inc.
+2.85%
+$28,311.03 
QURE uniQure N.V.
+2.8%
+$78,579 
OCUL Ocular Therapeutix Inc.
+2.76%
+$91,770 
KYTX Kyverna Therapeutics, Inc.
+2.35%
+$119,217.88 
VOR Vor Biopharma Inc.
+1.92%
+$84,926.61 
IVA Inventiva S.A.
+1.32%
+$36,233.9 
VRDN Viridian Therapeutics Inc.
+1.3%
+$44,134.23 
PHAT Phathom Pharmaceuticals Inc.
+0.97%
+$84,127.2 
CNTB Connect Biopharma Holdings Ltd.
+0.95%
+$4,189.86 
OBIO Orchestra BioMed Holdings, Inc.
+0.74%
+$26,901.03 
ABEO Abeona Therapeutics Inc.
0%
$0 
ACHV Achieve Life Sciences Inc.
0%
$0 
ATHA Athira Pharma, Inc.
0%
$0 
KMPH KemPharm, Inc.
0%
$0 
MIST Milestone Pharmaceuticals Inc.
0%
$0 
OCS
0%
$0 
UPB Upstream Bio, Inc.
-4.39%
-$95,698.12 
EVMN Evommune, Inc.
-4.16%
-$47,871.04 
PALI Palisade Bio Inc.
-3.93%
-$78,050 
MSLE Satellos Bioscience Inc.
-2.54%
-$1,521.75 
SABS Sab Biotherapeutics Inc.
-1.48%
-$50,639.5 
CHRS Coherus Biosciences Inc.
-1.41%
-$28,411 
AQST Aquestive Therapeutics Inc.
-0.95%
-$28,439.52 
KLRS Kalaris Therapeutics, Inc.
-0.69%
-$8,873.13 
CORT Corcept Therapeutics Incorporated
-0.41%
-$50,261.52 
DCTH Delcath Systems Inc.
-0.38%
-$44,086.41 
MAZE Maze Therapeutics Inc.
-0.17%
-$1,751.96 
FDMT 4D Molecular Therapeutics, Inc.
-0.06%
-$1,902.1 
PAGP Plains GP Holdings, L.P.
-0.04%
-$12,723.6 Events
Loading...
Dividends
Dividend Analysis
Loading...
No Data
| Trades 147 | Longs Won 52/147 35% | Profit Factor 0.99 |
| Profitability | Shorts Won 0/0 0% | Standard Deviation $2.11M |
| Average Win $1.15M | Best Trade (Jun 14) $12.06M | Sharpe Ratio -21.83 |
| Average Loss -$633,568.92 | Worst Trade (Dec 30) -$14.75M | Z-Score 0.96 (66.19%) |
| Commissions $0 | Avg. Trade Length 8m 1w 3d | Expectancy $8,030.51 |
| Loss Size | 100% | 90% | 80% | 70% | 60% | 50% | 40% | 30% | 20% | 10% |
| Probability of Loss | - | - | - | - | - | - | - | - | - | - |
| Consecutive Losing Trades | 280 | 252 | 224 | 196 | 168 | 140 | 112 | 84 | 56 | 28 |
Hover over the desired column for a detailed explanation.
Returns
Overall, MonthlyNo Data
Option values are updated at end of day.
No Data
No Data
Option values are updated at end of day.
No Data
No Data
No Data
No Data
